BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9930732)

  • 1. Effects of cyclin-dependent kinase inhibitors on transcription and ocular circadian rhythm of Aplysia.
    Sankrithi N; Eskin A
    J Neurochem; 1999 Feb; 72(2):605-13. PubMed ID: 9930732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker.
    Krucher NA; Meijer L; Roberts MH
    Cell Mol Neurobiol; 1997 Oct; 17(5):495-507. PubMed ID: 9353591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
    Monaco EA; Beaman-Hall CM; Mathur A; Vallano ML
    Biochem Pharmacol; 2004 May; 67(10):1947-64. PubMed ID: 15130771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of the phase and period of a circadian oscillator by a reversible transcription inhibitor.
    Raju U; Koumenis C; Nunez-Regueiro M; Eskin A
    Science; 1991 Aug; 253(5020):673-5. PubMed ID: 1871602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of a reversible transcription inhibitor, DRB, to investigate the involvement of specific proteins in the ocular circadian system of Aplysia.
    Koumenis C; Tran Q; Eskin A
    J Biol Rhythms; 1996 Mar; 11(1):45-56. PubMed ID: 8695892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
    Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
    Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
    Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
    Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
    Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
    Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
    Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM
    Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins.
    Schang LM; Rosenberg A; Schaffer PA
    J Virol; 2000 Mar; 74(5):2107-20. PubMed ID: 10666240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine.
    Yakisich JS; Sidén A; Idoyaga Vargas V; Eneroth P; Cruz M
    Biochem Biophys Res Commun; 1998 Feb; 243(3):674-7. PubMed ID: 9500988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hunt for mechanisms of circadian timing in the eye of Aplysia.
    Koumenis C; Eskin A
    Chronobiol Int; 1992 Jun; 9(3):201-21. PubMed ID: 1611674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
    Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
    Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
    Holcakova J; Muller P; Tomasec P; Hrstka R; Nekulova M; Krystof V; Strnad M; Wilkinson GW; Vojtesek B
    PLoS One; 2014; 9(2):e89228. PubMed ID: 24586613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
    Edamatsu H; Gau CL; Nemoto T; Guo L; Tamanoi F
    Oncogene; 2000 Jun; 19(27):3059-68. PubMed ID: 10871858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.
    Schang LM; Phillips J; Schaffer PA
    J Virol; 1998 Jul; 72(7):5626-37. PubMed ID: 9621021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases.
    Schang LM; Rosenberg A; Schaffer PA
    J Virol; 1999 Mar; 73(3):2161-72. PubMed ID: 9971799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of 6-DMAP, olomoucine and roscovitine on Xenopus oocytes and eggs.
    Flament S; Bodart JF; Bertout M; Browaeys E; Rousseau A; Vilain JP
    Zygote; 2000 Feb; 8(1):3-14. PubMed ID: 10840869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK-inhibitor olomoucine inhibits cell death after exposure of cell lines to cytosine-arabinoside.
    Papazisis KT; Geromichalos GD; Kouretas D; Dimitriadis KA; Kortsaris AH
    Cancer Lett; 1999 Apr; 138(1-2):221-6. PubMed ID: 10378797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.